Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Indications for a second prostate biopsy in patients suspected with prostate cancer after an initial negative prostate biopsy.

Lee KS, Koo KC, Cho KS, Lee SH, Han WK, Choi YD, Hong SJ, Park SU, Lee SY, Ko WJ, Kim YS, Chung BH.

Prostate Int. 2017 Mar;5(1):24-28. doi: 10.1016/j.prnil.2016.12.002. Epub 2016 Dec 23.

2.

MRI/Ultrasound Fusion Biopsy Versus Standard 12-Core Biopsy.

Weiss B, Loeb S.

Rev Urol. 2015;17(2):113-5. doi: 10.3909/riu0670b. Review. No abstract available.

3.

Endorectal multiparametric MRI of the prostate: incremental effect of perfusion imaging on biopsy target identification.

Romero G, Foster BR, Pettersson DR, Fung AW, Guimaraes AR, Coakley FV.

Clin Imaging. 2016 May-Jun;40(3):553-7. doi: 10.1016/j.clinimag.2016.01.011. Epub 2016 Jan 28.

PMID:
27133703
4.

Racial differences in the relationship between clinical prostatitis, presence of inflammation in benign prostate and subsequent risk of prostate cancer.

Rybicki BA, Kryvenko ON, Wang Y, Jankowski M, Trudeau S, Chitale DA, Gupta NS, Rundle A, Tang D.

Prostate Cancer Prostatic Dis. 2016 Jun;19(2):145-50. doi: 10.1038/pcan.2015.54. Epub 2015 Dec 1.

PMID:
26620738
5.

Detecting Prostate Cancer.

Brock M, von Bodman C, Palisaar J, Becker W, Martin-Seidel P, Noldus J.

Dtsch Arztebl Int. 2015 Sep 11;112(37):605-11. doi: 10.3238/arztebl.2015.0605.

6.

Prebiopsy MRI and MRI-ultrasound Fusion-targeted Prostate Biopsy in Men With Previous Negative Biopsies: Impact on Repeat Biopsy Strategies.

Mendhiratta N, Meng X, Rosenkrantz AB, Wysock JS, Fenstermaker M, Huang R, Deng FM, Melamed J, Zhou M, Huang WC, Lepor H, Taneja SS.

Urology. 2015 Dec;86(6):1192-8. doi: 10.1016/j.urology.2015.07.038. Epub 2015 Aug 31.

7.

Targeted Prostate Biopsy: Lessons Learned Midst the Evolution of a Disruptive Technology.

Nassiri N, Natarajan S, Margolis DJ, Marks LS.

Urology. 2015 Sep;86(3):432-8. doi: 10.1016/j.urology.2015.07.001. Epub 2015 Jul 10. Review.

8.

Characteristics of Detected and Missed Prostate Cancer Foci on 3-T Multiparametric MRI Using an Endorectal Coil Correlated With Whole-Mount Thin-Section Histopathology.

Tan N, Margolis DJ, Lu DY, King KG, Huang J, Reiter RE, Raman SS.

AJR Am J Roentgenol. 2015 Jul;205(1):W87-92. doi: 10.2214/AJR.14.13285.

9.

Multiparametric MRI guidance in first-time prostate biopsies: what is the real benefit?

Acar Ö, Esen T, Çolakoğlu B, Vural M, Onay A, Sağlıcan Y, Türkbey B, Rozanes İ.

Diagn Interv Radiol. 2015 Jul-Aug;21(4):271-6. doi: 10.5152/dir.2015.46014.

10.

RNA biomarkers to facilitate the identification of aggressive prostate cancer.

Pellegrini KL, Sanda MG, Moreno CS.

Mol Aspects Med. 2015 Nov;45:37-46. doi: 10.1016/j.mam.2015.05.003. Epub 2015 May 27. Review.

11.

Prostate cancer detection rate in patients with fluctuating prostate-specific antigen levels on the repeat prostate biopsy.

Park YH, Lee JK, Jung JW, Lee BK, Lee S, Jeong SJ, Hong SK, Byun SS, Lee SE.

Prostate Int. 2014 Mar;2(1):26-30. doi: 10.12954/PI.13037. Epub 2014 Mar 30.

12.

Targeted prostate biopsy: value of multiparametric magnetic resonance imaging in detection of localized cancer.

Le JD, Huang J, Marks LS.

Asian J Androl. 2014 Jul-Aug;16(4):522-9. doi: 10.4103/1008-682X.122864. Review.

13.

Standards for prostate biopsy.

Bjurlin MA, Taneja SS.

Curr Opin Urol. 2014 Mar;24(2):155-61. doi: 10.1097/MOU.0000000000000031. Review.

14.

Markers for detection of prostate cancer.

Clarke RA, Schirra HJ, Catto JW, Lavin MF, Gardiner RA.

Cancers (Basel). 2010 Jun 4;2(2):1125-54. doi: 10.3390/cancers2021125.

15.

Technology diffusion and diagnostic testing for prostate cancer.

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Miller DC, Weizer AZ, Montgomery JS, Wei JT, Shahinian VB, Hollenbeck BK.

J Urol. 2013 Nov;190(5):1715-20. doi: 10.1016/j.juro.2013.05.007. Epub 2013 May 10.

16.

Obesity and future prostate cancer risk among men after an initial benign biopsy of the prostate.

Rundle A, Jankowski M, Kryvenko ON, Tang D, Rybicki BA.

Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):898-904. doi: 10.1158/1055-9965.EPI-12-0965. Epub 2013 Apr 23.

17.

Five-year downstream outcomes following prostate-specific antigen screening in older men.

Walter LC, Fung KZ, Kirby KA, Shi Y, Espaldon R, O'Brien S, Freedland SJ, Powell AA, Hoffman RM.

JAMA Intern Med. 2013 May 27;173(10):866-73. doi: 10.1001/jamainternmed.2013.323.

18.

Accuracy analysis in MRI-guided robotic prostate biopsy.

Xu H, Lasso A, Guion P, Krieger A, Kaushal A, Singh AK, Pinto PA, Coleman J, Grubb RL 3rd, Lattouf JB, Menard C, Whitcomb LL, Fichtinger G.

Int J Comput Assist Radiol Surg. 2013 Nov;8(6):937-44. doi: 10.1007/s11548-013-0831-9. Epub 2013 Mar 27.

19.

Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen.

Sonn GA, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Dorey FJ, Reiter RE, Marks LS.

Eur Urol. 2014 Apr;65(4):809-15. doi: 10.1016/j.eururo.2013.03.025. Epub 2013 Mar 17.

20.

Methylation of the RARB gene increases prostate cancer risk in black Americans.

Tang D, Kryvenko ON, Mitrache N, Do KC, Jankowski M, Chitale DA, Trudeau S, Rundle A, Belinsky SA, Rybicki BA.

J Urol. 2013 Jul;190(1):317-24. doi: 10.1016/j.juro.2013.01.083. Epub 2013 Jan 30.

Supplemental Content

Support Center